Oliver Sartor, MD | Authors


Targeting PSMA in Advanced Prostate Cancer

March 30, 2021

Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.

Dr. Oliver Sartor on Doubling the Dosage of Radium-223 in Patients With CRPC

February 06, 2016

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses how radium-223 dichloride became deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC). The treatment was tested in an open-label phase I/II trial where patients were given 6 additional doses of radium-223 on top of their original 6-dose regimen.

Dr. Oliver Sartor on the Future of Identifying Phenotypic and Genomic Heterogeneity in mCRPC

January 08, 2016

Sartor says the test would lay out molecular data regarding a patient's malignancy and allow community oncologists to determine what would be the best course of treatment. He added that the hope for this study is to replace the "trial and error" method of treatment with something more concrete.